UBE3A and Angelman syndrome: Three ongoing phase I clinical trials are assessing the safety of ASOs targeting a noncoding transcript (UBE3A-ATS) to activate paternal UBE3A gene expression in individuals with Angelman syndrome (NCT04259281, NCT04428281, and NCT05127226) (Figure 2G).